Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenues:
Royalties	$ 3,060	$ 1,993
Material sales	667	1,019
Collaborative research and development and other revenues	1,909	884
Total revenues	5,636	3,896
Operating costs and expenses:
Cost of sales	155	525
Research and development	2,817	1,986
General and administrative	3,503	3,445
Lease exit and termination costs	(74)	(151)
Total operating costs and expenses	6,401	5,805
Accretion of deferred gain on sale leaseback		426
Loss from operations	(765)	(1,483)
Other income (expense):
Interest income	17	37
Interest expense	(792)	(423)
Decrease (increase) in contingent liabilities	513	(2,288)
Other, net	254	48
Total other income (expense), net	(8)	(2,626)
Loss before income taxes	(773)	(4,109)
Income tax benefit (expense)	35	13,730
Income (loss) from continuing operations	(738)	9,621
Discontinued operations:
Income tax benefit (expense) on discontinued operations	(177)
Discontinued operations	1,871	4
Net income	1,133	9,625
Basic and diluted per share amounts:
Income (Loss) from continuing operations	$ (0.04)	$ 0.49
Discontinued operations	$ 0.10
Net income	$ 0.06	$ 0.49
Weighted average number of common shares-basic and diluted	19,709,078	19,623,249
AVINZA Product Line [Member]
Discontinued operations:
Gain on sale of Product Line before income taxes	2,048
Oncology Product Line [Member]
Discontinued operations:
Gain on sale of Product Line before income taxes		$ 4